These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 19917699)

  • 21. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine.
    Qin X; Guo BT; Wan B; Fang L; Lu L; Wu L; Zang YQ; Zhang JZ
    J Immunol; 2010 Aug; 185(3):1855-63. PubMed ID: 20622114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-myeloablative transplantation of bone marrow expressing self-antigen establishes peripheral tolerance and completely prevents autoimmunity in mice.
    Hosseini H; Oh DY; Chan ST; Chen XT; Nasa Z; Yagita H; Alderuccio F; Toh BH; Chan J
    Gene Ther; 2012 Nov; 19(11):1075-84. PubMed ID: 22071968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population.
    Li H; Nourbakhsh B; Ciric B; Zhang GX; Rostami A
    J Immunol; 2010 Oct; 185(7):4095-100. PubMed ID: 20805418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines.
    Lees JR; Iwakura Y; Russell JH
    J Immunol; 2008 Jun; 180(12):8066-72. PubMed ID: 18523270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis.
    Domingues HS; Mues M; Lassmann H; Wekerle H; Krishnamoorthy G
    PLoS One; 2010 Nov; 5(11):e15531. PubMed ID: 21209700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis.
    Kanakasabai S; Walline CC; Chakraborty S; Bright JJ
    Brain Res; 2011 Feb; 1376():101-12. PubMed ID: 21192919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies to myelin oligodendrocyte glycoprotein are not involved in the severity of chronic non-remitting experimental autoimmune encephalomyelitis.
    Sekiguchi Y; Ichikawa M; Takamoto M; Ota H; Koh CS; Muramatsu M; Honjo T; Agematsu K
    Immunol Lett; 2009 Feb; 122(2):145-9. PubMed ID: 18824198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes.
    Jäger A; Dardalhon V; Sobel RA; Bettelli E; Kuchroo VK
    J Immunol; 2009 Dec; 183(11):7169-77. PubMed ID: 19890056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells.
    Chen SJ; Wang YL; Kao JH; Wu SF; Lo WT; Wu CC; Tao PL; Wang CC; Chang DM; Sytwu HK
    Mol Immunol; 2009 Dec; 47(2-3):567-74. PubMed ID: 19819554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haptoglobin deficiency facilitates the development of autoimmune inflammation.
    Galicia G; Maes W; Verbinnen B; Kasran A; Bullens D; Arredouani M; Ceuppens JL
    Eur J Immunol; 2009 Dec; 39(12):3404-12. PubMed ID: 19795414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.
    Abad C; Jayaram B; Becquet L; Wang Y; O'Dorisio MS; Waschek JA; Tan YV
    J Neuroinflammation; 2016 Jun; 13(1):169. PubMed ID: 27357191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis.
    Zhang GX; Yu S; Gran B; Li J; Siglienti I; Chen X; Calida D; Ventura E; Kamoun M; Rostami A
    J Immunol; 2003 Nov; 171(9):4485-92. PubMed ID: 14568921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.
    Bettelli E; Das MP; Howard ED; Weiner HL; Sobel RA; Kuchroo VK
    J Immunol; 1998 Oct; 161(7):3299-306. PubMed ID: 9759845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD30 ligand is a new therapeutic target for central nervous system autoimmunity.
    Shinoda K; Sun X; Oyamada A; Yamada H; Muta H; Podack ER; Kira J; Yoshikai Y
    J Autoimmun; 2015 Feb; 57():14-23. PubMed ID: 25533628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in nonobese diabetic mice by increasing Th1 and Th17 cells.
    Lin MH; Yeh LT; Chen SJ; Chiou HY; Chu CC; Yen LB; Lin KI; Chang DM; Sytwu HK
    Clin Immunol; 2014 Apr; 151(2):101-13. PubMed ID: 24568746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kirenol attenuates experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells.
    Xiao J; Yang R; Yang L; Fan X; Liu W; Deng W
    Sci Rep; 2015 Mar; 5():9022. PubMed ID: 25762107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The
    Gorman JA; Hundhausen C; Kinsman M; Arkatkar T; Allenspach EJ; Clough C; West SE; Thomas K; Eken A; Khim S; Hale M; Oukka M; Jackson SW; Cerosaletti K; Buckner JH; Rawlings DJ
    Front Immunol; 2019; 10():44. PubMed ID: 30740104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis.
    Thakker P; Leach MW; Kuang W; Benoit SE; Leonard JP; Marusic S
    J Immunol; 2007 Feb; 178(4):2589-98. PubMed ID: 17277169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GCN2 kinase plays an important role triggering the remission phase of experimental autoimmune encephalomyelitis (EAE) in mice.
    Orsini H; Araujo LP; Maricato JT; Guereschi MG; Mariano M; Castilho BA; Basso AS
    Brain Behav Immun; 2014 Mar; 37():177-86. PubMed ID: 24362236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-Th17 Axis.
    Mangalam AK; Rattan R; Suhail H; Singh J; Hoda MN; Deshpande M; Fulzele S; Denic A; Shridhar V; Kumar A; Viollet B; Rodriguez M; Giri S
    J Immunol; 2016 Aug; 197(3):747-60. PubMed ID: 27354217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.